

CITATION REPORT

List of articles citing

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

DOI: 10.1186/1471-2377-9-63
BMC Neurology, 2009, 9, 63.

Source: <https://exaly.com/paper-pdf/45876203/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
116	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. 2010 , 120, 385-99		65
115	The roles of TNF in brain dysfunction and disease. 2010 , 128, 519-48		153
114	Alzheimer disease and HIV: a tangled story. 2010 , 75, 105-6		4
113	Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. <i>BMC Neurology</i> , 2010 , 10, 51	3.1	36
112	Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. 2010 , 7, 10		42
111	HIV-associated neurocognitive disorders: a changing pattern. 2011 , 6, 81-95		4
110	Antibodies against insulin measured by electrochemiluminescence predicts insulinitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status. 2011 , 9, 203		17
109	HIV-1 reduces A β -degrading enzymatic activities in primary human mononuclear phagocytes. 2011 , 186, 6925-32		19
108	Impact of antiretroviral therapy on HIV-related brain injury. 2011 , 52, 244-7		
107	HIV-1 infection and cognitive impairment in the cART era: a review. 2011 , 25, 561-75		167
106	HIV-1 Nef in macrophage-mediated disease pathogenesis. 2012 , 31, 432-50		28
105	Cerebral A β deposition predicts HIV-associated neurocognitive disorders in APOE ϵ 4 carriers. 2012 , 26, 2327-35		82
104	The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. 2012 , 9, 3		24
103	Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease. 2012 , 6, 371-6		4
102	Cerebrospinal fluid proteome of patients with acute Lyme disease. 2012 , 11, 4814-22		12
101	HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. 2012 , 2, a007120		142
100	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimer's disease and related conditions. 2012 , 2, 117-123		

99	Cerebrospinal fluid profiles of amyloid β -related biomarkers in Alzheimer's disease. 2012 , 14, 65-73	61
98	Autophagy in dementias. 2012 , 22, 99-109	48
97	HIV-associated neurocognitive disorder. 2013 , 13, 976-86	374
96	Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. 2013 , 8, 1147-58	35
95	Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. 2013 , 260, 620-6	67
94	Cerebrospinal fluid biomarkers of β -amyloid metabolism in multiple sclerosis. 2013 , 19, 543-52	37
93	Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. 2013 , 207, 1703-12	120
92	Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration. 2013 , 20, 420-428	61
91	Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. 2013 , 5, 47	31
90	HIV-associated neurocognitive disease: case studies and suggestions for diagnosis and management in different patient subgroups. 2014 , 19, 1-13	8
89	Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers. 2013 , 71, 689-92	6
88	Efavirenz promotes β -secretase expression and increased A β -40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). 2014 , 9, e95500	43
87	Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. 2014 , 9, e116081	70
86	HIV and aging: effects on the central nervous system. 2014 , 34, 27-34	40
85	Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. 2014 , 28, 2251-8	100
84	Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. 2014 , 89, 607-14	14
83	Brain viral burden, neuroinflammation and neurodegeneration in HAART-treated HIV positive injecting drug users. <i>Journal of NeuroVirology</i> , 2014 , 20, 28-38	3.9 34
82	CSF A β -42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. 2014 , 10, 381-92	53

81	Verbal memory declines more rapidly with age in HIV infected versus uninfected adults. 2014 , 36, 356-67	52
80	CSF in Alzheimer's disease. 2014 , 65, 143-72	18
79	Central nervous system HIV-1 infection. 2014 , 123, 487-505	9
78	HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. 2014 , 11, 317-24	66
77	Role of HIV in amyloid metabolism. 2014 , 9, 483-91	43
76	Clinical Aspects of HIV-Related Neurocognitive Disorders. 2014 , 107-156	
75	Cerebrospinal Fluid from Alzheimer's Disease Patients Contains Fungal Proteins and DNA. 2015 , 47, 873-6	22
74	The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease. 2015 , 12, 23	15
73	Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders. 2015 , 13, 43-54	41
72	Cerebrospinal fluid analysis in the HIV infection and compartmentalization of HIV in the central nervous system. 2015 , 73, 624-9	7
71	Chronic Infectious Inflammatory Diseases of the Central Nervous System. 2015 , 211-245	1
70	Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. 2015 , 2, ofv037	35
69	APOE ϵ moderates abnormal CSF- β 42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. <i>BMC Neurology</i> , 2015 , 15, 51	3.1 40
68	HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?. 2015 , 7, 37	89
67	Amyloid biomarkers in Alzheimer's disease. 2015 , 36, 297-309	320
66	Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children. 2016 , 95, e3093	17
65	Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis : CSF Biomarkers of SIV Encephalitis. 2016 , 11, 332-47	1
64	Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals. 2016 , 30, 1533-42	34

63	HIV/neuroAIDS biomarkers. 2017 , 157, 117-132	18
62	PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy. 2017 , 44, 895-902	18
61	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. 2017 , 17, 761-770	70
60	Therapeutic Considerations in HIV-Associated Neurocognitive Disorders. 2017 , 737-751	1
59	Biomarkers of Disorders of the Nervous System. 2017 , 463-610	1
58	Differentiating HIV-Associated Neurocognitive Disorders From Alzheimer's Disease: an Emerging Issue in Geriatric NeuroHIV. 2017 , 14, 123-132	52
57	Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. 2017 , 31, F9-F17	64
56	Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection. 2017 , 31, 973-979	16
55	Ex vivo O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway. 2017 , 12, 18	15
54	No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau). 2017 , 8, 599-604	8
53	An Overview of Human Immunodeficiency Virus Type 1-Associated Common Neurological Complications: Does Aging Pose a Challenge?. 2017 , 60, S169-S193	9
52	Alzheimer's Amyloid- β is an Antimicrobial Peptide: A Review of the Evidence. 2018 , 62, 1495-1506	109
51	Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. 2018 , 221-252	1
50	HIV-1 Nef is released in extracellular vesicles derived from astrocytes: evidence for Nef-mediated neurotoxicity. 2017 , 8, e2542	75
49	Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. <i>Journal of NeuroVirology</i> , 2018 , 24, 28-40	3.9 13
48	Cerebrospinal fluid in the dementias. 2017 , 146, 85-97	9
47	"APP"reciating the complexity of HIV-induced neurodegenerative diseases. 2018 , 14, e1007309	3
46	Neurocognitive Impairment and Associated Genetic Aspects in HIV Infection. 2021 , 50, 41-76	1

45	Alterations in brain TREM2 and Amyloid- β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy. <i>Journal of Neurochemistry</i> , 2018 , 147, 784-802	6	16
44	The Physiological Roles of Amyloid- β Peptide Hint at New Ways to Treat Alzheimer's Disease. 2018 , 10, 118		140
43	Commentary: Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. 2018 , 9, 201		21
42	Alzheimer's disease neuropathology may not predict functional impairment in HIV: a report of two individuals. <i>Journal of NeuroVirology</i> , 2018 , 24, 629-637	3.9	8
41	Characterization of Cerebrospinal Fluid BACE1 Species. 2019 , 56, 8603-8616		4
40	The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease. <i>Journal of NeuroVirology</i> , 2019 , 25, 661-672	3.9	15
39	Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review. 2019 , 6, 2049936119838228		12
38	Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. <i>Journal of NeuroVirology</i> , 2019 , 25, 150-161	3.9	16
37	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. 2019 , 16, 76-81		4
36	Diagnostic and prognostic biomarkers for HAND. <i>Journal of NeuroVirology</i> , 2019 , 25, 686-701	3.9	9
35	Blood amyloid- β protein isoforms are affected by HIV-1 in a subtype-dependent pattern. <i>Journal of NeuroVirology</i> , 2020 , 26, 3-13	3.9	7
34	Predictive biomarkers for cognitive decline during progressive HIV infection. 2020 , 51, 102538		2
33	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. 2020 , 12, 123		10
32	Beta amyloid levels in cerebrospinal fluid of HIV-infected people vary by exposure to antiretroviral therapy. 2020 , 34, 1001-1007		7
31	HIV-1 Tat-mediated astrocytic amyloidosis involves the HIF-1 α /lncRNA BACE1-AS axis. 2020 , 18, e3000660		14
30	Biomarkers and Their Role in Detection of Biomolecules. 2020 , 73-94		2
29	HIV-1 infection and latency-reversing agents bryostatatin-1 and JQ1 disrupt amyloid beta homeostasis in human astrocytes. 2020 , 68, 2212-2227		3
28	Morphine and HIV-1 Tat interact to cause region-specific hyperphosphorylation of tau in transgenic mice. 2021 , 741, 135502		7

27	Magnetic resonance imaging changes in Asian people living with HIV. 2021 , 53, 89-93		0
26	Brain and Central Nervous System Infections: Viruses. 2021 ,		
25	Alzheimer Dementia in People Living With HIV. 2021 , 11, e627-e633		4
24	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. 2021 , 16, e0250987		5
23	Clinical Utility of β Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. 2021 , 87, 826-833		1
22	Advances in the Experimental Models of HIV-Associated Neurological Disorders. 2021 , 18, 459-474		2
21	Alzheimer's-Like Pathology at the Crossroads of HIV-Associated Neurological Disorders. 2021 , 9,		3
20	Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study. 2020 , 10, 22400		1
19	Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies. 2020 , 10, 200286		5
18	Lower CSF A β s Associated with HAND in HIV-Infected Adults with a Family History of Dementia. 2016 , 14, 324-30		4
17	The Serum Amyloid β Level in Multiple Sclerosis: A Case- Control Study. 2017 , 3, 214-221		1
16	Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	8
15	Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression. <i>Frontiers in Immunology</i> , 2021 , 12, 737941	8.4	0
14	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. 2014 , 131-157		
13	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.		
12	Central nervous system complications of HIV infection. <i>Topics in Antiviral Medicine</i> , 2011 , 19, 48-57	3.2	11
11	Higher Cerebrospinal Fluid Biomarkers of Neuronal Injury in Hiv-Associated Neurocognitive Impairment. <i>SSRN Electronic Journal</i> ,	1	
10	CSF markers of AD-related pathology relate specifically to memory impairment in older people with HIV: a pilot study.. <i>Journal of NeuroVirology</i> , 2022 , 1	3.9	1

9	Amyloid processing in COVID-19 associated neurological syndromes.. <i>Journal of Neurochemistry</i> , 2022 ,	6	2
8	Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition.. <i>Viruses</i> , 2022 , 14,	6.2	1
7	Neurodegeneration Within the Amygdala Is Differentially Induced by Opioid and HIV-1 Tat Exposure. <i>Frontiers in Neuroscience</i> , 2022 , 16,	5.1	1
6	Quantitative proteomic analysis of cerebrospinal fluid reveals CD163, A2M and full-length APP as potential diagnostic biomarkers of paediatric bacterial meningitis.. <i>Proteome Science</i> , 2022 , 20, 8	2.6	
5	Progressive Degeneration and Adaptive Excitability in Dopamine D1 and D2 Receptor-Expressing Striatal Neurons Exposed to HIV-1 Tat and Morphine. <i>Cellular and Molecular Neurobiology</i> ,	4.6	1
4	Higher cerebrospinal fluid biomarkers of neuronal injury in HIV-associated neurocognitive impairment. <i>Journal of NeuroVirology</i> ,	3.9	0
3	Complement component 3 and complement factor H protein levels are altered in brain tissues from people with human immunodeficiency virus: A pilot study. 14,		0
2	Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes. 2022 ,		0
1	Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial.		0